Physician profile
Nancy S Wolfin
NPI 1407940687
$12,572.02
in general payments reported to CMS, 2019-2025
36 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what 79% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $1,734 · 2021: $1,333 · 2022: $1,928 · 2023: $2,977 · 2024: $1,501 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,264 · Education: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.41 |
| Education | $405.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,341.35 | 2019-2025 | Skyrizi |
| Incyte Corporation | $1,254.23 | 2021-2025 | Opzelura |
| Pfizer INC. | $908.35 | 2019-2025 | |
| Janssen Biotech, INC. | $907.46 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $744.94 | 2019-2025 | |
| Dermavant Sciences, INC. | $703.20 | 2023-2024 | Vtama |
| Genentech USA, INC. | $627.97 | 2019-2024 | Erivedge, Actemra |
| Arcutis Biotherapeutics, INC. | $544.98 | 2023-2024 | Zoryve |
| Vyne Pharmaceuticals INC. | $506.68 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $504.38 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $496.30 | 2020-2025 | Nemluvio, Aklief, Twyneo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $472.04 | 2019-2025 | Jublia, Cabtreo |
| Almirall LLC | $433.71 | 2019-2023 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $415.93 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $414.05 | 2020-2025 | Winlevi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $369.54 | 2019-2025 | Adbry, Anzupgo |
| Verrica Pharmaceuticals INC. | $212.51 | 2023 | Ycanth |
| Lilly USA, LLC | $206.71 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Journey Medical Corporation | $180.00 | 2025 | |
| Amgen INC. | $177.48 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $167.25 | 2022-2025 | |
| Encore Dermatology INC. | $121.12 | 2019-2020 | |
| Epi Health, LLC | $117.09 | 2020-2022 | |
| Biofrontera INC. | $102.56 | 2019-2020 | |
| Sandoz INC. | $94.23 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Mayne Pharma Commercial LLC | $84.50 | 2019-2021 | |
| Glenmark Therapeutics INC. | $81.00 | 2019 | |
| Organon LLC | $72.81 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $72.62 | 2019-2024 | Xtrac |
| Botanix Sb INC | $39.44 | 2025 | Sofdra |
| Stemline Therapeutics INC. | $31.25 | 2020 | |
| Celgene Corporation | $24.68 | 2019 | |
| Aclaris Therapeutics, INC. | $21.08 | 2019 | |
| Dermira, INC. | $17.72 | 2020 | |
| Merck Sharp & Dohme LLC | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Wolfin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.